RxDoctor Payments Data

Dharmendra Patel, MD

Ophthalmology · Scottsdale, AZNPI 1255314597

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,700 of the $19,987 with a category attached, or 73.5%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 75.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $15,594 and has fallen 98.5% since, to $236 in 2025. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,987in general payments, 2019–2025

Across 41 payments — averaging $487.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$15K
  • Eyepoint US, Inc.$3K
  • Ivantis, Inc$1K
  • Glaukos Corporation$320
  • Medtronic$173
  • Alcon$154
  • plus $371 from 6 others

What the payments were for

  • Consulting fees$2,20011%
  • Speaking & faculty fees$14,70074%
  • Travel & lodging$1,2076%
  • Food & beverage$1,8799%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,987 in reported general payments places this provider in the 90th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$388,789
Medicare patients
686
Services billed
3,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost141$84,259
CombiganBrimonidine Tartrate/Timolol44$20,179
RestasisCyclosporine16$18,602
VyzultaLatanoprostene Bunod50$16,849
Brimonidine Tartrate112$7,251
Prednisolone Acetate98$5,537
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat237$5,483
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$5,031
RocklatanNetarsudil Mesylat/Latanoprost14$4,841
Travoprost19$3,266
Latanoprost365$3,009
Cosopt PfDorzolamide/Timolol/Pf13$2,696
Dorzolamide Hcl48$1,162
Ofloxacin59$691
Timolol Maleate27$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$54$16,84950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →